Navigation Links
RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum
Date:9/17/2013

r-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contacts

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a designer ... & Marketing Director. , With more than 25 years of experience in ... Tronics’ business development activities worldwide. He brings to the company his strong expertise ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading,international pharmaceutical ... 31, 2007., 2007 Full Year Financial Highlights:, - ... in 2006 - Chemical Division,s ... $45.8 million in 2006. ...
... 31 NxStage Medical,Inc. (Nasdaq: NXTM ), ... that Tom Shea has joined the Company as ... 2008. Mr.,Shea will be responsible for all of ... Mr. Shea joins NxStage with more than ...
... MANASQUAN, NJ., March 31 BioSpace, the world,s leading,online ... will host,the Biotech Beach(TM) Career in La Jolla, CA ... at the Hyatt Regency La Jolla from 2 pm-7 ... science professionals from across Southern California will attend,the biotech ...
Cached Biology Technology:Dragon Pharma announces 2007 full year financial results 2Dragon Pharma announces 2007 full year financial results 3Dragon Pharma announces 2007 full year financial results 4Dragon Pharma announces 2007 full year financial results 5Dragon Pharma announces 2007 full year financial results 6Dragon Pharma announces 2007 full year financial results 7NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 2NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 3Bioscience Career Fair in San Diego Expected to Draw Record Jobseeker Attendance 2
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market Intelligence,s ... The Convergence of Commerce and Privacy" forecasts that ... biometric apps will be downloaded to smart mobile ... mobile biometrics market is projected to generate more ... during the seven-year forecast period.    ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... Ceramic Society (ACerS) today announced that two companies, Corning ... the organization,s 2010 Corporate Technical Achievement Award for their ... Scan Scintillator, respectively. "We somewhat broke with tradition ... very remarkable products and companies," says ACerS President Edwin ...
... is a response that differs from one animal or ... researchers at Tel Aviv University are challenging what we ... helping clinicians better treat victims of terrorism or natural ... student Rony Izhar of Tel Aviv University,s Department of ...
... by researchers at the National Institute of Standards and ... of a powerfulbut trickydiagnostic technique for cell biology. The ... demonstrates that with improved hardware and better signal ... quickly deliver detailed molecular maps of the contents of ...
Cached Biology News:Corning, GE Healthcare to receive Technical Achievement Award from Ceramic Society 2Is anxiety contagious? 2Is anxiety contagious? 3Faster CARS, less damage: NIST chemical microscopy shows potential for cell diagnostics 2
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse polyclonal antibody to BAG2 - BCL2-associated athanogene 2...
... a partial recombinant IFNA2. Immunogen: ... is produced in E. coli. The biological ... OMIM: 147562, ... MM951100564 MA Code: ABV0P9DPB ...
Biology Products: